Pay in 4 interest-free payments of $6.93 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
Who is the GLP-1 Companion Bundle designed for
Telehealth has dramatically simplified access to GLP-1 prescriptions
Choose the best setting for your wellness goals
It is especially important to consult with your healthcare provider for specific exercise guidance in the case of diastasis recti
CV outcomes for adult patients with type 2 diabetes and established cardiovascular disease LEADERa landmark CVOT for Victoza 1 9,340 patients Key inclusion criteria: T2D, A1C 7.0% Age 50 years and established CVD OR Age 60 years and risk factors for CVD Cardiovascular standards of care (antihypertensives, lipid-lowering agents, and antiplatelet therapy) Diabetes standards of care (lifestyle modification, OADs, and insulin) Duration 3.5-5 years Time to first major adverse cardiovascular event (MACE) composed of: Composite primary endpoint CV death Nonfatal MI Nonfatal stroke Prospectively designed and powered to assess noninferiority and then superiority Patients were titrated to maximum tolerated dose of 0.6 mg to 1.8 mg Median daily dose of Victoza was 1.78 mg Victoza significantly reduced MACE in adults with T2D and established CVD 1 Absolute risk reduction: 1.9% Median time of exposure to treatment: 3.5 years
In unimolecular GLP-1R/GCGR dual agonist studies 14,15,16,17 , the ratios of the GLP-1R and GCGR potencies have varied and typically have been significantly greater than 1:1 despite evidence that an evenly balanced, 1:1 ratio results in optimal metabolic effects 18
